BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years

British Journal of Cancer

Volumn 106, Issue 6, 2012, Pages 1234-1238

  Robertson, L ^a,b   Hanson, H ^a,c   Seal, S ^a   Warren Perry, M ^a   Hughes, D ^a   Howell, I ^a   Turnbull, C ^a   Houlston, R ^a   Shanley, S ^b   Butler, S ^c   Evans, D G ^d   Ross, G ^b   Eccles, D ^e   Tutt, A ^f   Rahman, N ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d ST MARY S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

BRCA1; breast cancer; genetic testing; triple negative

Indexed keywords

BRCA1 PROTEIN;

ADULT; AGE; ARTICLE; CANCER DIAGNOSIS; FAMILY HISTORY; GENE FREQUENCY; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; UNITED KINGDOM;

AGE FACTORS; BRCA1 PROTEIN; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC TESTING; HUMANS; INCIDENCE; MIDDLE AGED; MUTATION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84858295021     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.31     Document Type: Article

References (26)

1. American Society of Clinical Oncology (2003) American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer Susceptibility. J Clin Oncol 21: 2397-2406
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117-1130 (Pubitemid 36530000)
3. Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, Shanley S, Pichert G, Izatt L, Rose S, Douglas F, Eccles D, Morrison PJ, Scott J, Zimmern RL, Easton DF, Pharoah RPD (2008) Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 45: 425-431 (Pubitemid 351977132)
4. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26: 4282-4288
5. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triplenegative phenotype: a population-based study from the California cancer Registry. Cancer 109: 1721-1728 (Pubitemid 46668532)
6. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10 159 cases from 12 studies. PLoS Med 7: e1000279
7. Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE (2009) Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol 33: 1093-1097
8. Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M (2011) Relative contributions of BRCA1 and BRCA2 mutations to 'triplenegative' breast cancer in Ashkenazi Women. Breast Cancer Res Treat 129: 185-190
9. Eccles D, Gerty S, Simmonds P, Hammond V, Ennis S, Altman DG, POSH steering group (2007) Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. BMC Cancer 7: 160
10. Evans DG, Howell A, Ward D, Lalloo F, Jones JL, Eccles DM (2011) Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet 48: 520-522
11. Evans DG, Lalloo F, Cramer A, Jones EA, Knox F, Amir E, Howell A (2009) Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 46: 811-817
12. Evans DG, Lalloo F, Wallace A, Rahman N (2005) Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J MedGenet 42: e39
13. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134
14. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363: 1938-1948
15. Gadzicki D, Evans DG, Harris H, Julian-Reynier C, Nippert I, Schmidtke J, Tibben A, van Asperen CJ, Schlegelberger B (2011) Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Comm Genet 2: 53-69
16. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17: 1082-1089
17. Kilburn LS, TNT Trial Management Group (2008) 'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials. Clin Oncol (R Coll Radiol) 20: 35-39
18. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B (2010) Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28: 4214-4220
19. Mavaddat N, Rebbeck TR, Lakhani SR, Easton DF, Antoniou AC (2010) Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res 12: R28
20. McIntosh A, Shaw C, Evans G, Turnbull N, Bahar N, Barclay M, Easton D, Emery J, Gray J, Halpin J, Hopwood P, McKay J, Sheppard C, Sibbering M, Watson W, Wailoo A, Hutchinson A (2004) Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. In NICE Clinical Guideline 14. National Collaborating Centre for Primary Care/University of Sheffield: London
21. NICE (2006) Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. In NICE Clinical Guideline 41 (Partial Update of Clinical Guideline 14). http://www.nice.org.uk/nicemedia/live/10994/30244/30244.pdf
22. Nathanson KL, Domchek SM (2011) Therapeutic approaches for women predisposed to breast cancer. Annu Rev Med 62: 295-306
23. Office for National Statistics (2006) Cancer Statistics Registrations, England (Series MB1), No. 37. London http://www.ons.gov.uk/ons/rel/vsob1/ cancerstatistics-registrations-england-series-mb1-/no-37-2006/index.html
24. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235-244
25. Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakili I, Royer R, Li S, Narod SA (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9: 86
26. Zhang J, Pei R, Pang Z, Ouyang T, Li J,Wang T, Fan Z, Fan T, Lin B, Xie Y (2011) Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer. Breast Cancer Res Treat; e-pub ahead of print 26 May 2011; doi:10.1007/s10549-011-1596-x